First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study
Identificadores
Identificadores
Data de publicación
2012Título da revista
ONCOLOGIST
Tipo de contido
Artigo